Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders

References

• DE Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15–22.
   PubMed Web of Science ®Google Scholar
• Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147–156.
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–817.
   PubMed Web of Science ®Google Scholar
• Kouidrat Y, Amad A, De Hert M. Emerging drugs and indications for cardio-metabolic disorders in people with severe mental illness. Curr Pharm Des. 2015;21(23):3317–3324.
   Web of Science ®Google Scholar
• Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39(6):1174–1179.
   PubMed Web of Science ®Google Scholar
• Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74(6):400–409.
   PubMed Web of Science ®Google Scholar
• Jakobsson J, Bjerke M, Sahebi S, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci. 2015;40(4):250–258.
   PubMed Web of Science ®Google Scholar
• Moises HW, Wollschläger D, Binder H. Functional genomics indicate that schizophrenia may be an adult vascular-ischemic disorder. Transl Psychiatry. 2015;5:e616.
   Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11(6):851–876.
   PubMed Web of Science ®Google Scholar
• Wood SJ, Yücel M, Pantelis C, et al. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore. 2009;38(5):396–401.
   PubMed Web of Science ®Google Scholar
• Jorgensen A, Siersma V, Davidsen AS, et al. Markers of DNA/RNA damage from oxidation as predictors of a registry-based diagnosis of psychiatric illness in type 2 diabetic patients. Psychiatry Res. 2018;259:370–376.
   Web of Science ®Google Scholar
• Kim HK, Andreazza AC, Yeung PY, et al. Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J Psychiatry Neurosci. 2014;39(4):276–285.
   Web of Science ®Google Scholar
• Maas DA, Vallès A, Martens GJM. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry. 2017;7(7):e1171.
   Google Scholar
• Nedic Erjavec G, Konjevod M, Nikolac Perkovic M, et al. Short overview on metabolomic approach and redox changes in psychiatric disorders. Redox Biol. 2018;14:178–186.
   PubMed Web of Science ®Google Scholar
• Meier MH, Shalev I, Moffitt TE, et al. Microvascular abnormality in schizophrenia as shown by retinal imaging. Am J Psychiatry. 2013;170(12):1451–1459.
   Web of Science ®Google Scholar
• Hosak L, Hakeem K, Raad M, et al. Is microvascular abnormality a new endophenotype in schizophrenia? Psychiatr Danub. 2015;27(3):225–229.
   Web of Science ®Google Scholar
• Ota M, Sato N, Sakai K, et al. Altered coupling of regional cerebral blood flow and brain temperature in schizophrenia compared with bipolar disorder and healthy subjects. J Cereb Blood Flow Metab. 2014;34(12):1868–1872.
   Web of Science ®Google Scholar
• Burtis CA, Ashwood ER. Tietz fundamentals of clinical chemistry. Philadelphia (PA): W.B Saunders; 2001.
   Google Scholar
• Baltanás FC, Weruaga E, Valero J, et al. Albumin attenuates DNA damage in primary-cultured neurons. Neurosci Lett. 2009;450(1):23–26.
   PubMed Web of Science ®Google Scholar
• Yao X, Miao W, Li M, et al. Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. Neurosci Lett. 2010;472(3):179–183.
   Web of Science ®Google Scholar
• Mizrahi EH, Blumstein T, Arad M, et al. Serum albumin levels predict cognitive impairment in elderly hip fracture patients. Am J Alzheimers Dis Other Demen. 2008;23(1):85–90.
   Web of Science ®Google Scholar
• Peters Jr. T. All about albumin: biochemistry, genetics and medical applications. San Diego, New York, Boston, London, Sydney, Tokyo, Toronto: Academic Press; 1996.
   Google Scholar
• Sadler PJ, Tucker A, Viles JH. Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. comparison with Co2+, Cd2+, Al3+. Eur J Biochem 1994;220(1):193–200.
   PubMedGoogle Scholar
• Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol. 2006;108(3):410–411.
   PubMed Web of Science ®Google Scholar
• Balta S, Aparci M, Demir M, et al. Ischemia-modified albumin in patients with seizure. Am J Emerg Med. 2014;32(10):1282.
   Web of Science ®Google Scholar
• Bar-Or D, Lau E, Rao N, et al. Reduction in the cobalt binding capacity of human albumin with myocardial ischemia. Ann Emerg Med. 1999;34(4):S56.
   Google Scholar
• Balta S, Alemdar R, Erdogan S, et al. Ischemia modified albumin in cardiovascular disease. Am J Emerg Med. 2016;34(8):1699.
   Web of Science ®Google Scholar
• McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312(3):159–163.
   PubMed Web of Science ®Google Scholar
• Berenshtein E, Mayer B, Goldberg C, et al. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J Mol Cell Cardiol. 1997;29(11):3025–3034.
   Web of Science ®Google Scholar
• Sitar ME, Aydin S, Cakatay U. Human serum albumin and its relation with oxidative stress. Clin Lab. 2013;59(9-10):945–952.
   PubMed Web of Science ®Google Scholar
• Adly AAM, ElSherif NHK, Ismail EAR, et al. Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major. Redox Rep. 2017;22(6):430–438.
   PubMed Web of Science ®Google Scholar
• Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet. 2009;24(4):333–341.
   PubMed Web of Science ®Google Scholar
• Rawdin BJ, Mellon SH, Dhabhar FS, et al. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun. 2013;31:143–152.
   PubMed Web of Science ®Google Scholar
• Dahake HS, Ghangle S, Warade J, et al. Study of nonenzymatic antioxidants in schizophrenic patients. International Journal of Research in Medical Sciences. 2016;4(9):3768–3772.
   Google Scholar
• Réus GZ, Fries GR, Stertz L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015;300:141–154.
   PubMed Web of Science ®Google Scholar
• Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98(3):247–252.
   Web of Science ®Google Scholar
• Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132(2):97–108.
   PubMed Web of Science ®Google Scholar
• Gude D, Byrapaneni RB. Ischaemia modified albumin: does it bolster our diagnostic ammunition? Indian J Anaesth. 2011;55(4):408–411.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, et al. Washington (DC): American Psychiatric Press; 1997.
   Google Scholar
• Özkürkçügil A, Aydemir Ö, Yıldız M, et al. DSM-IV Eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçe’ye uyarlanması ve güvenilirlik çalışması. İlaç ve Tedavi Derg. 1999;12(4):233–236.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Akdemir A, Önsel S, Dağ İ, et al. Hamilton depresyon derecelendirme ölçeği (HDDÖ)’nin geçerliği, güvenirliği ve klinik kullanımı. Psikiyatri Psikol Psikofarmakol Derg. 1996;4:251–259.
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
   PubMed Web of Science ®Google Scholar
• Karadağ F, Oral ET, Aran Yalçın F, et al. Young mani derecelendirme ölçeğinin Türkiye’de geçerlik ve güvenilirliği. Türk Psikiyatri Derg. 2001;13:107–114.
   Google Scholar
• Andreasen NC. The scale for the assesment of positive symtoms (SAPS). Iowacity (IA): University of Iowa Press, ; 1984.
   Google Scholar
• Erkoç Ş, Arkonaç O, Ataklı C, et al. Pozitif semptomları değerlendirme ölçeğinin güvenirliği ve geçerliliği. Düşünen Adam. 1991;4:20–24.
   Google Scholar
• Andreasen NC. The scale for the assesment of negative symptoms (SANS). Iowacity (IA): University of Iowa Press; 1983.
   Google Scholar
• Erkoç Ş, Arkonaç O, Ataklı C, et al. Negatif semptomları değerlendirme ölçeğinin güvenirliği ve geçerliliği. Düşünen Adam. 1991;4:16–19.
   Google Scholar
• Williams JB. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry. 1988;45(8):742–747.
   PubMed Web of Science ®Google Scholar
• Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–1182.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19(4):311–315.
   PubMed Web of Science ®Google Scholar
• Apple FS, Quist HE, Otto AP, et al. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem. 2002;48(7):1097–1100.
   PubMed Web of Science ®Google Scholar
• Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205–212.
   Web of Science ®Google Scholar
• Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 2000;97(2-3):137–151.
   PubMed Web of Science ®Google Scholar